ArticleJournal of hematology & oncology2026

UVI5008: the first reversible, non-covalent Bruton's tyrosine kinase epi-inhibitor for B-cell malignancies.

Carmela Dell'Aversana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.